VolitionRX (VNRX) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
VolitionRX is the larger company by market cap ($6.6 million vs $2.7 million), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | VNRX | VRAX |
|---|---|---|
| Share price | $0.2194 | $1.99 |
| Market cap | $6.60M | $2.68M |
| 1-day change | -2.92% | -5.69% |
| EPS (TTM) | $-3.80 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.80 | $21.75 |
| 52-week low | $0.217 | $1.83 |
| Distance from 52-week high | -98.29% | -90.85% |
| Analyst consensus | none | — |
| Avg. price target upside | +6107.84% | — |
| Average volume | 8.46M | 650.11K |
| Shares outstanding | 30.06M | 1.34M |
| Employees | 57 | 26 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VolitionRX is about 2.5 times larger than Virax Biolabs Group by market value ($6.60M vs $2.68M).
About VolitionRX
VNRX stock →VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
Healthcare · Medical Devices · 57 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Healthcare · Biotechnology · 26 employees
VNRX vs VRAX FAQ
Which is bigger, VolitionRX or Virax Biolabs Group?
VolitionRX (VNRX) is larger, with a market capitalization of $6.60M compared with $2.68M for Virax Biolabs Group (VRAX).
Are VolitionRX and Virax Biolabs Group in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for VolitionRX and Biotechnology for Virax Biolabs Group.